Go to Main

Organelle Therapeutics, Inc.(CEO Eun-jung Jin) has been successfully selected for the 2025 Startup Growth Technology Development Program('Didimdol') with its project, 'Development of Peroxisome Based Gene Therapy for Osteoarthritis.' This program aims to support technology development for the innovative growth of technology-based startup powerhouse through strategic R&D support for startups.

Through this project, Organelle Therapeutics Inc. plans to develop a gene local delivery hydrogel technology utilizing panththenic acid-incorporated hyaluronic acid and advance its peroxisome-based gene therapy production platform for musculoskeletal disorders.

Eun-jung Jin, CEO of Organelle Therapeutics Inc. stated "Being selected for this 'Didimdol project' officially recognizes our innovative gene therapy technology and growth potential," adding, "we will continue to dedicate ourselves to developing biopharmaceuticals that imporve patients's quality of life and leap forward as a gobal biotech company."